It remains to be seen whether such approaches will be able to overcome interpatient and intratumoral variability in protease expression and achieve sufficient discrimination between tumor and healthy tissue to widen IL2’s therapeutic index in patients. The gene discussed is IL2; the disease is neoplasm.